Integrating long-acting injectable cabotegravir for HIV prevention into the Brazilian public health system ImPrEP CAB Brasil: a hybrid type-2 implementation-effectiveness cohort study


Grinsztejn B, Torres TS, Hoagland B, Coutinho C, Silva MST, Leite IC, Cunha M, Derrico M, Jalil EM, Cardoso SW, Trefiglio R, Farias A, Mourão MPG, Madruga JV, de Lima JN, Zonta R, O'Malley G, Moreira J, Simpson K, Rinehart AR, Pilgrim N, Hellstrom A, Cameron AI, Luz PM, Landovitz RJ, Benedetti M, Pimenta C, Moreira RI, Veloso VG; Integrating long-acting injectable cabotegravir for HIV prevention into the Brazilian public health system ImPrEP CAB Brasil: a hybrid type-2 implementation-effectiveness cohort study. Lancet HIV. 2026 Sep 24:S2352-3018(26)00201-8. doi: 10.1016/S2352-3018(26)00201-8. Epub ahead of print. PMID: 42785335.


Related Posts